NULIBRY™ (fosdenopterin) – Synthetic cPMP for MoCD Type A

TRUSELTIQ™ (high-dose infigratinib) – FGFR1-3 inhibitor for cholangiocarcinoma

Acoramidis (AG10) – TTR stabilizer for transthyretin amyloidosis (ATTR)

High-dose infigratinib – FGFR1-3 inhibitor for urothelial carcinoma (urinary tract and bladder cancer)

Low-dose infigratinib – FGFR1-3 inhibitor for achondroplasia

Encaleret – Ca sensing receptor antagonist for autosomal dominant hypocalcemia type 1 (ADH1)

BBP-418 – Glycosylation substrate pro-drug for limb-girdle muscular dystrophy 21 (LGMD2i)

BBP-589 – Recombinant collagen for recessive dystrophic epidermolysis bullosa (RDEB)

BBP-812 – AAV9 gene therapy for Canavan disease

BBP-398 – SHP2 inhibitor for tumors driven by RAS and receptor tyrosine kinase mutations

BBP-671 – PanK inhibitor for pantothenate kinase-associated neurodegeneration (PKAN) and organic acidemias (OA)

Subramanian C & Jackowski S. Sci Transl Med. 2021 Sep 15;13(611). doi: 10.1126/scitranslmed.abf5965.

Subramanian C & Jackowski S. Sci Transl Med. 2021 Sep 15;13(611). doi: 10.1126/scitranslmed.abf5965.

BBP-631 – AAV5 gene therapy for congenital adrenal hyperplasia (CAH)

BridgeBio

presentations & publications

BridgeBio is committed to letting science speak. Here we have gathered a selection of publications relevant to our programs.

 

links to an external site

indicates a PDF download